Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study

NCT00114023 is registered in ClinicalTrials.gov with Graceway Pharmaceuticals, LLC as lead sponsor.

NCT NCT00114023
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00114023 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Follow-up Study to Evaluate Actinic Keratosis Recurrence Rates One Year After Completion of the 1473-IMIQ Study
Lead sponsor
Graceway Pharmaceuticals, LLC
Phase
Observational
Overall status
Completed
Start date
January 31, 2005
Completion date
Not reported
Enrollment
84
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

keratosis